Arecor receives £2.8 million grant award from Innovate UK

Coveted award for Phase II clinical development of lead product, AT247, its next generation ultra-rapid acting Insulin Cambridge, UK., 31st Mar 2021: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces … Continued

Calculus Capital delivers 6x return with ActiveOps listing

ActiveOps admitted to trading on AIM today IPO to pay out £21 million to Calculus investors Calculus Capital portfolio company ActiveOps has completed a successful Initial Public Offering on the Alternative Investment Market, generating an impressive 6x return for Calculus … Continued

Yourgene Genomic Services portfolio expansion

Cytox’s genoSCORETM-LAB test can predict the risk of developing Alzheimer’s disease Yourgene Genomic Services to run the array-based test at Citylabs 1.0 in Manchester Manchester, UK – 11 March 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene … Continued

Open Orphan wins contract with Oxford Biotherapeutics

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its subsidiary Venn Life Sciences (“Venn”) has been awarded a contract for a study with Oxford … Continued

Celebrating Women in Leadership

Today, on International Women’s Day 2021, we join companies around the globe celebrating the social, economic, cultural, and political achievements of women. International Women’s Day #IWD2021 is an annual reminder to not only recognise and champion greater female representation but … Continued

Support for the creative industries

The creative sector makes a remarkable contribution to the UK economy It is integral to the UK’s economic and social regeneration £400m budget bonus to support the arts British stars dominated at Sunday evening’s Golden Globes virtual awards ceremony with … Continued

Calculus VCT – zero initial fee offer

Normal initial fees of 3-5% waived for a limited period in the run up to the end of the tax year. Award-winning Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) specialist, Calculus Capital, is waiving initial fees on its VCT … Continued